TIMOTHY DEREGO: Open Payments
NPI 1013756154 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,111 in 41 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $486 · 2025 $1,111
Food & beverage: $1,111
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $288 |
| GENZYME CORPORATION | 7 | $247 |
| Janssen Biotech, Inc. | 3 | $73 |
| Phathom Pharmaceuticals, Inc. | 4 | $72 |
| Celltrion USA Inc. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Lilly USA, LLC | 2 | $63 |
| Intercept Pharmaceuticals, Inc. | 2 | $55 |
| Aimmune Therapeutics, Inc. | 1 | $35 |
| Ardelyx, Inc. | 1 | $35 |
Products named: XIFAXAN, DUPIXENT, TREMFYA, VOQUEZNA, VEGZELMA, EOHILIA, OMVOH, OCALIVA.
Industry payments across CA — which companies pay providers there.
